| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 0.0 | 0.0 | 0.0 |
| Other income | 7.6 | 0.7 | 0.2 |
| Total income | 7.6 | 0.7 | 0.2 |
| Profit before exceptional items & tax | -56.9 | -31.6 | -0.2 |
| Profit before tax | -56.9 | -31.6 | -0.2 |
| Net profit | -67.9 | 14.3 | -130.1 |
| Operating margin | -748.7% | n/m | -100.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
BSE results filing, NSE: NECLIFE. Figures extracted from the filing.
Nectar Lifesciences Ltd: key numbers
- Share price
- ₹10.84
- Market cap
- ₹243.1 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹-292.9 Cr
- P/E (TTM)
- -1.0×Sector 50.4×
- Promoter holding
- 51.84%+0.00% QoQ
- FII holding
- 0.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nectar Lifesciences Ltd
All →Nectar Lifesciences Management Change
Nectar Lifesciences Limited has announced the appointment of Dr. Gunmala Suri as a Director. Additionally, three other directors have been re-appointed to the Board.
Nectar Lifesciences Annual General Meeting
Nectar Lifesciences filed proceedings of its 31st AGM held September 18, 2026. Resolutions covered adoption of FY26 financials and director re-appointments.
Nectar Lifesciences Q1 FY27 Results: Net Loss of ₹15.4 Cr, Loss Narrows
Nectar Lifesciences Ltd reported revenue from operations of ₹0.4 Cr and a net loss of ₹15.4 Cr for Q1 FY27.
- Key figure
- Net loss ₹15.4 Cr